Patent US2350462A successfully refreshed from Google Patents.
US4094977A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Combination preparation of estrogen and prostaglandin
Assignee: Hoechst AG
•
Filing: 1976-06-24
•
Granted: 1978-06-13
•
Expires: 1996-06-24
Abstract
Abstract A pharmaceutical combination preparation which comprises as active substances at least one compound selected from the group of the luteolytically effective prostaglandins or derivatives thereof and at least one compound selected from the group of the estrogenic substances, in a weight ratio of from 1:1 to 1:5,000, in admixture with the usual adjuvants and/or carrier material.
Inventors
- 👤 Karl Seeger
- 👤 Fritz Bauer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 16:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565; A61K31/557
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
51 words
A leutolytically-active pharmaceutical composition comprising an injectable or orally-administrable carrier and, as the active ingredient, a combination of at least one luteolytically effective prostaglandin or a physiologically acceptable salt or ester thereof and at least one estrogen or an ester or ether thereof in a weight ratio from 1:1 to 1:5000.
Claim 2
Dependent Claim
51 words
A leutolytically-active pharmaceutical composition comprising an injectable or orally-administrable carrier and, as the active ingredient, a combination of at least one luteolytically effective prostaglandin or a physiologically acceptable salt or ester thereof and at least one estrogen or an ester or ether thereof in a weight ratio from 1:1 to 1:5000.
Claim 3
Dependent Claim
24 words
A pharmaceutical composition as in claim 1 wherein the luteolytically effective ingredient is a 9α,11α,15-trihydroxy-5-cis,13-trans-prostadienic acid or a physiologically acceptable salt or ester thereof.
Claim 4
Dependent Claim
42 words
A pharmaceutical composition as in claim 1 wherein the luteolytically effective ingredient is a homolog of a 9α,11α,15-trihydroxy-5-cis,13-trans-prostadienic acid, said homolog having a side chain containing from 4 to 10 unsubstituted or substituted carbon atoms in the side chain in the 12-position.
Claim 5
Dependent Claim
21 words
A pharmaceutical composition as in claim 1 wherein the luteolytically effective ingredient is a 17-oxaor 18-oxa- derivative of a 9α,11α,15-trihydroxy-5-cis,13-transprostadienic acid.
Claim 6
Dependent Claim
17 words
A pharmaceutical composition as in claim 1 wherein said estrogen is a natural or semisynthetic steroidal estrogen.
Claim 7
Dependent Claim
14 words
A pharmaceutical composition as in claim 1 wherein said estrogen is a non-steroidal estrogen.
Claim 8
Dependent Claim
22 words
A pharmaceutical composition as in claim 1 which additionally comprises a gonadotropin or an agent having a stimulating effect on the uterus.
Claim 9
Dependent Claim
40 words
A method for synchronizing estrus in a commercially-reared animal which comprises orally or parenterally administering to said animal, between the 5th day and 20th day of the estrus cycle, a luteolytically effective amount of the pharmaceutical composition of claim 1.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-06-12 | 1981-12-12 | 1982-06-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-06-12 | 1985-12-12 | 1986-06-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-06-12 | 1989-12-12 | 1990-06-13 | $7700.00 | Window Closed / Lapsed |